抗PD-1/PD-L1药物在黑色素瘤治疗中的基础及应用  

Research and clinical application of anti-programmed death-1 and anti-programmed death-ligand 1 drugs in melanoma treatment

作　　者：乔昱[1] 马家芳[2] 

机构地区：[1]北京医院肿瘤科,北京100730 [2]北京大学肿瘤医院日间化疗病房,北京100142

出　　处：《世界临床药物》2015年第6期423-426,共4页World Clinical Drug

摘　　要：常规化疗手段治疗黑色素瘤效果欠佳,肿瘤免疫治疗是近年研究热点。表达于T淋巴细胞表面的程序性死亡受体1(PD-1)和表达于抗原呈递细胞表面的程序性死亡受体配体1(PD-L1)的结合与肿瘤细胞免疫逃逸相关,阻断PD-1与PD-L1的结合有望克服免疫耐受。本文综述抗PD-1/PD-L1的理论基础及近年抗PD-1/PD-L1药物在黑色素瘤临床治疗中的应用。The rising incidence and historical poor response to chemotherapy have led to intense investigation of novel treatments for melanoma. Recently, the development of immunotherapy has generated great excitement. It is known that the engagement of T-cell programmed death-1(PD-1) with programmed death-ligand 1(PD-L1) expressed by cancer cells and antigen-presenting cells can inhibit immunity and allow tumor to grow. Thereby inhibition of the interaction between PD-1and PD-L1 becomes a new strategy to improve the immune tolerance and facilitate destruction of cancer cells. This review discusses the preclinical rationale and clinical application of anti- PD-1/ PD-L1 drugs in melanoma treatment.

关 键 词：免疫治疗 黑色素瘤 程序性死亡受体1(PD-1) 程序性死亡受体配体1(PD-L1) 

分 类 号：R739.5[医药卫生—肿瘤]